Donor variability among anti-inflammatory pre-activated mesenchymal stromal cells.

ABSTRACT: Therapeutic mesenchymal stromal cells (MSCs) are attractive in part due to their immunomodulatory properties, achieved by their paracrine secretion of factors including prostaglandin E2 (PGE2). Despite promising pre-clinical data, demonstrating clinical efficacy has proven difficult. The current studies were designed to develop approaches to pre-induce desired functions from naïve MSCs and examine MSC donor variability, two factors contributing to this disconnect. MSCs from six human donors were pre-activated with interleukin 1 beta (IL-1?) at a concentration and duration identified as optimal or interferon gamma (IFN-?) as a comparator. Their secretion of PGE2 after pre-activation and secondary exposure to pro-inflammatory molecules was measured. Modulation of tumor necrosis factor alpha (TNF-?) secretion from M1 pro-inflammatory macrophages by co-cultured pre-activated MSCs was also measured. Our results indicated that pre-activation of MSCs with IL-1? resulted in upregulated PGE2 secretion post exposure. Pre-activation with IL-1? or IFN-? resulted in higher sensitivity to induction by secondary stimuli compared to no pre-activation. While IL-1? pre-activation led to enhanced MSC-mediated attenuation of macrophage TNF-? secretion, IFN-? pre-activation resulted in enhanced TNF-? secretion. Donor variability was noted in PGE2 secretion and upregulation and the level of improved or impaired macrophage modulation.

SUBMITTER: Gray A 

PROVIDER: S-EPMC5932627 | biostudies-literature | 2016 Sep

REPOSITORIES: biostudies-literature